ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taylor, D. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, D. O.
Related Collections
Right arrow Mechanical Circulatory Assistance

Ann Thorac Surg 2003;75:S72-S78
© 2003 The Society of Thoracic Surgeons

Supplement

Cardiac transplantation: drug regimens for the 21st century

David O. Taylor, MDa*

a Department of Cardiovascular Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, USA

* Address reprint requests to Dr Taylor, Department of Cardiovascular Diseases, Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F-25, Cleveland, OH 44195, USA.
e-mail: taylord2{at}ccf.org

Presented at the Heart Failure & Circulatory Support Summit, Cleveland, OH Aug 22–25, 2002.

Abstract

Survival with congestive heart failure has improved significantly over the last 20 years. However, many patients continue to progress to end-stage disease and suffer unacceptable morbidity and mortality. In the current era, survival after cardiac transplantation approaches 88% to 90% by 1 year at most centers, with more than 50% of patients surviving more than 10 years. Thus, for end-stage patients who are acceptable candidates, cardiac transplantation remains the treatment of choice. The majority of the early (<30-day) postoperative mortality relates to allograft quality and surgical issues, whereas the majority of deaths after 30 days relates to issues of "over" or "under" immunosuppression. With an early mortality rate of less than 10%, the majority of deaths occur after 30 days. Thus a "perfect" immunosuppression regimen would save more lives than a "perfect" donor heart or surgical procedure. Immunosuppression continues to improve but we are all striving for the "perfect" regimen: one free of adverse side effects with perfect graft function. Only a protocol with no chronic immunosuppressive drugs, in other words, complete allograft tolerance, will accomplish this. Many fascinating tolerance-inducing strategies are currently under development.




This article has been cited by other articles:


Home page
 Card Surg AdultHome page
L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner
Heart Transplantation
Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578.
[Full Text]

Home page
 Circ. Res.Home page
A. Morgun, N. Shulzhenko, A. Perez-Diez, R. V.Z. Diniz, G. F. Sanson, D. R. Almeida, P. Matzinger, and M. Gerbase-DeLima
Molecular Profiling Improves Diagnoses of Rejection and Infection in Transplanted Organs
Circ. Res., June 23, 2006; 98(12): e74 - e83.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
A. Lembcke, S. Dushe, S. Sonntag, C. Kloeters, C. N. H. Enzweiler, T. H. Wiese, B. Hamm, F.-X. Kleber, and W. F. Konertz
Changes in right ventricular dimensions and performance after passive cardiac containment
Ann. Thorac. Surg., September 1, 2004; 78(3): 900 - 905.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.